Phase 1Not yet recruitingAge-related condition
Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome
A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of MiraMSC Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome
- Sponsor
- Miracle Biomedical Co., Ltd. (Industry)
- Enrollment
- 12 planned
- Conditions
- Frailty
- Interventions
- MiraMSC-FS-001
- Ages
- adults, older adults
- Registry
- NCT07705464
Full record on ClinicalTrials.gov
From the registry
The purpose of this Phase I, open-label study is to evaluate the safety and tolerability of intravenous MiraMSC-FS-001 in older adults with mild to moderate frailty syndrome. MiraMSC-FS-001 is an investigational product consisting of allogeneic umbilical cord-derived mesenchymal stem cells (UCMSCs). Eligible participants will receive intravenous administration of MiraMSC-FS-001.
Primary outcomes
- Maximum Feasible Dose (MFD) of MiraMSC-FS-001
- Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)
History
Primary completion expected
Expected to start
Registered